Drawing for MONONUCLEAR THERAPEUTICS

USPTO serial 88221539

MONONUCLEAR THERAPEUTICS

Reviewed by CopyMark Law Group

Reg. 6148263Status 700Renewal
Filing date
Status date
Registration date
Sep 8, 2020
Examiner
MEYERS, MORGAN LAURA
Law office
PUBLICATION AND ISSUE SECTION

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with MONONUCLEAR THERAPEUTICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,097*

Plus Government fees of $1,275

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Susan J. Brushaber

Susan J. Brushaber Reinhardt Savic Foley LLP5613 South Prince Street, Suite 200Littleton, CO 80120UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
039Storage and retrieval of blood, tissue and stem cells for medical research, treatment and diagnostics; storage and retrieval of blood and blood components for medical research; biomedical services namely, the storage of human cells, specifically umbilical cord blood, umbilical cord blood cells, and stem cells for medical use and research useACTIVENov 1, 2019
042Research and development services in cellular therapy, in particularly, research and development in the field of treatment and medical diagnosis using cellular, molecular, biotechnological and genetic methods, and in the field of development of mononuclear cell therapy; research and development of individualized medicine, development of treatment plan and therapy adapted for individual patients; biomedical laboratory services for others, namely, the collection, extraction, processing, cryopreservation, analysis, screening, testing, typing and storage of umbilical cord blood, placenta, human tissues and stem cells; genetic testing services for research purposes; consultation, research and development relating to scientific research; research and development relating to medicine and healthcare products; development of testing methods in the fields of cellular therapy and mononuclear cell therapyACTIVENov 1, 2019
044Collection and testing of cord blood, blood, blood components, tissue and stem cells for medical research; medical diagnostic testing relating to cord blood, placenta tissue, human bodyACTIVENov 1, 2019

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 8, 2025REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Dec 22, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Dec 22, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 22, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 8, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 1, 2020SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Jul 31, 2020CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Jul 8, 2020SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Jul 8, 2020AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jun 17, 2020IUAFUSE AMENDMENT FILED—
Jun 17, 2020EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Jan 29, 2020ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 29, 2020REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Dec 17, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Oct 22, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 22, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 2, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 25, 2019ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 25, 2019REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 18, 2019ALIEASSIGNED TO LIE—
Sep 15, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 14, 2019XAECEXAMINER'S AMENDMENT ENTERED—
Sep 14, 2019GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Sep 14, 2019GNEAEXAMINERS AMENDMENT E-MAILED—
Sep 14, 2019CNEAEXAMINERS AMENDMENT -WRITTEN—
Sep 7, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 6, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 6, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 13, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 13, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 13, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 6, 2019DOCKASSIGNED TO EXAMINER—
Jan 1, 2019MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Dec 30, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 11, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance